fashion -WSS

fashion

author：comprehensive 2025-10-01 17:56:58 - browse：425

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： High breast density mammograms need follow

focus

WSS

Flu vaccine reformulation won't be easy, manufacturers warn

Heart attack and stroke risk calculators need revising

Medicare drug price lawsuits could be good politics for Biden

Prior authorization reform is both possible and imperative

Medicare drug price lawsuits could be good politics for Biden

Printout prescription drug information shouldn’t go digital

hotspot

fashion

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA sets aggressive timeline for overhauling inspection procedures

Cancer drug shortages should be causing more outrage

DIEP, the 'gold standard' of breast reconstruction, is under threat

In age of alternative facts, a scholarly course on calling out crap

Wildfire smoke exposes gaps in outdoor worker protections

Dobbs anniversary: the lost opportunity of abortion as health care

Dog Aging Project founders on what lies ahead after losing funding

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

entertainment

At least 13 dead in Texas as scorching temps continue

Supreme Court strikes down use of affirmative action

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA sets aggressive timeline for overhauling inspection procedures

Novavax promises a turnaround & Lilly roils the obesity market

How one medical school became remarkably diverse

focus

focus

focus

explore